We currently have numerous trials enrolling new participants. They include:
- Anal Cancer Prevention in HIV Patients
- Clostridium difficile Infection (Recurrent)
- Cognitive Impairment/Dementia
- Nephrotic Syndrome
- Rheumatoid Arthritis
- Rosacea (Facial)
- Ulcerative Colitis
If you decide to take part in a clinical trial and are enrolled, you will receive confidential study-related medical care and treatment at no cost. Visits will be at The Polyclinic and free parking is provided. Financial compensation for time and travel may also be available.
We appreciate your interest and welcome the opportunity to speak with you directly. Please contact us at:
- Phone: 206-860-5433
- Email: firstname.lastname@example.org
Dr. Juan de la Ossa is conducting a study comparing topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer. Learn more.
Clostridium difficile Infection (Recurrent)
Clostridium difficile infection (CDI) is a bacterial infection of the gut (intestine). Many people who have CDI are successfully treated with antibiotics, but this doesn’t work for everyone. For some people, CDI occurs over and over again. This type of CDI is called “recurrent CDI.” Dr. Tony Trinh is conducting a study evaluating an investigational enema for the prevention of recurrent CDI. Patients must have had at least three episodes of CDI associated diarrhea and completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization within the last year. Learn more.
Dr. Braden Nago is conducting a study assessing how the results of an amyloid PET scan may impact treatment decisions. To be eligible patients must have mild cognitive impairment (MCI) or dementia of uncertain cause and be a Medicare beneficiary, 65 years of age or older. Enrolled patients will have one amyloid PET scan followed by one visit with Dr. Nago to discuss the results of the scan and future treatment. Medicare has agreed to cover the cost of the scan for this study. The scan is FDA approved and not considered investigational. Learn more.
Dr. Anne Pesenson is collaborating with NephCure Kidney International and offering patients the opportunity to take part in the NephCure Kidney Network Patient Registry, a nationwide research registry for patients with kidney diseases that cause Nephrotic Syndrome. The Registry is a chance for patients to help researchers find better treatments and the cure for the rare diseases that cause nephrotic syndrome. To be eligible, patients must be an established Polyclinic patient with a diagnosis of a condition associated with primary nephrotic syndrome. Learn more.
Dr. Anthony Krajcer is conducting a study to determine whether using results from a blood test called Vectra DA to guide drug dosing strategies can lower healthcare costs, without a negative impact on health and well-being, when compared to usual care. Patients must have active rheumatoid arthritis, and have not responded fully to methotrexate (MTX). Learn more.
Dr. Kim Abson is conducting a study evaluating an investigational topical foam for the treatment of facial rosacea. Patients must have moderate to severe facial rosacea, defined as the presence of at least 12 and not more than 50 inflammatory facial lesions (papules/pustules).
Dr. Peggy Headstrom is conducting a study evaluating an investigational drug in inducing clinical remission of ulcerative colitis. Patients must have moderate to severe active ulcerative colitis and demonstrated an inadequate response to, loss of response to, or intolerance to corticosteroids, immunosuppressants and/or biologic therapies. Learn more.